Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cutsnews2025-05-01T14:44:20+00:00May 1st, 2025|Endpoints News|
Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffsnews2025-04-30T14:43:09+00:00April 30th, 2025|Endpoints News|
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer datanews2025-04-29T14:20:06+00:00April 29th, 2025|Endpoints News|
Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europenews2025-04-28T14:59:47+00:00April 28th, 2025|Endpoints News|
Merck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on clinical holdnews2025-04-25T14:23:22+00:00April 25th, 2025|Endpoints News|
Avidicure’s $50M seed round; Flagship’s new AI company that detects diseasenews2025-04-24T14:52:29+00:00April 24th, 2025|Endpoints News|
Veraxa makes a SPAC deal; Illumina discloses layoffsnews2025-04-23T14:25:41+00:00April 23rd, 2025|Endpoints News|
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal termsnews2025-04-22T14:46:32+00:00April 22nd, 2025|Endpoints News|
Novartis terminates knee pain study; Telix reports brain tumor datanews2025-04-16T14:38:02+00:00April 16th, 2025|Endpoints News|
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5Mnews2025-04-15T14:35:42+00:00April 15th, 2025|Endpoints News|
